References
- Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, etal. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation. 2005; 111: 2446–53.
- American Diabetes Association. Implications of the diabetes control and complication trial. Diabetes Care. 2003; 26: 525–7.
- Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998; 17: 548–55.
- Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willett WC, etal. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care. 2004; 27: 2211–16.
- Guallar E, Jiménez FJ, van 't Veer P, Bode P, Riemersma RA, Gomez-Aracena J, etal. Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol. 2005; 162: 157–64.
- Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc. 2004; 63: 41–7.
- Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care. 2004; 27: 2741–51.
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids. Diabetes Care. 2007; 30: 2154–63.
- Hummel M, Standl E, Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Dis. 2007; 39: 743–51.
- Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, etal. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997; 46: 1786–91.
- Nielsen F. Controversial chromium: does the superstar mineral of the mountebanks receive appropriate attention from clinicians and nutritionists?. Nutr Today. 1996; 31: 226–33.
- Jain SK, Croad JL, Velusamy T, Rains JL, Bull R. Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NF-κB, Akt, and Glut-2 in livers of zucker diabetic fatty rats. Mol Nutr Food Res. 2010; 54: 1–10.
- Jain SK, Kahlon G, Moorehead L, Dhawan R, Lieblong B, Stapleton T, etal. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study. Mol Nutr Food Res. 2012; 56: 1333–41.
- Yaturu S, Daberry B, Rains J, Jain S-K. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine. 2006; 34: 219–23.
- Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32: 193–203.
- Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal. 2007; 9: 955–69.
- Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005; 7: 1040–52.
- Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal. 2011; 15: 1911–26.